Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle

Journal of Virology

Volumn 80, Issue 14, 2006, Pages 6993-7008

  Majid, Ayaz M ^a   Ezelle, Heather ^a   Shah, Sangeeta ^a   Barber, Glen N ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CORE PROTEIN; DRUG VEHICLE; GAMMA INTERFERON; GLYCOPROTEIN E1; GLYCOPROTEIN E2; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HCV E2; NONPROPAGATING VESICULAR STOMATITIS VIRUS CORE GLYCOPROTEIN E1 E2; UNCLASSIFIED DRUG; VESICULAR STOMATITS VIRUS CORE GLYCOPROTEIN E1 E2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CELL STRAIN BHK; COIMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPRECIPITATION; IMMUNOTHERAPY; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FOLDING; REPLICATION DEFECTIVE VESICULAR STOMATITIS VIRUS; VESICULAR STOMATITIS VIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; ANTIBODY FORMATION; CD8-POSITIVE T-LYMPHOCYTES; CRICETINAE; DISEASE MODELS, ANIMAL; EVALUATION STUDIES; FEMALE; GENETIC VECTORS; HELA CELLS; HEPATITIS B VACCINES; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNIZATION; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; VACCINIA VIRUS; VESICULAR STOMATITIS-INDIANA VIRUS; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

HEPATITIS C VIRUS; MURINAE; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 33745776471     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00365-06     Document Type: Article

References (80)

1. Adams, D. O., T. Hall, Z. Steplewski, and H. Koprowski. 1984. Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proc. Natl. Acad. Sci. USA 81:3506-3510.
2. Afdhal, N. H. 2004. The natural history of hepatitis C. Semin. Liver Dis. 24(Suppl. 2):3-8.
3. Agnello, V., A. Gyorgy, M. Elfahal, G. B. Knight, and Q.-X. Zhang. 1999. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sic. USA 96:12765-12771.
4. Balachandran, S., and G. N. Barber. 2000. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 50:135-138.
5. Balachandran, S., M. Porosnicu, and G. N. Barber. 2001. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or Myc function and involves induction of apoptosis. J. Virol. 75:3474-3479.
6. Ball, L. A., C. R. Pringle, B. Flanagan, V. P. Perepelitsa, and G. W. Wertz. 1999. Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. J. Virol. 73:4705-4712.
7. Barber, G. N. 2004. Vesicular stomatitis virus as an oncolytic vector. Viral Immunol. 17:516-527.
8. Bartenschlager, R., and V. Lohmann. 2000. Replication of the hepatitis C virus. Bailliere's Best Pract. Res. Clin. Gastroenterol. 14:241-254.
9. Barth, H., C. Schafer, M. I. Adah, F. Zhang, R. J. Linhardt, H. Toyoda, A. Kinoshita-Toyoda, T. Toida, T. H. Van Kuppevelt, E. Depla, F. Von Weizsacker, H. E. Blum, and T. F. Baumert. 2003. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 278:41003-41012.
10. Branch, A. D., D. D. Stump, J. A. Gutierrez, F. Eng, and J. L. Walewski. 2005. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others. Semin. Liver Dis. 25:105-117.
11. Brinster, C., M. Chen, D. Boucreux, G. Baccala-Paranhos, P. Liljestrom, F. Lemmonier, and G. Inchauspe. 2002. Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J. Gen. Virol. 83:369-381.
12. Bruna-Romero, O., J. J. Lasarte, G. Wilkinson, K. Grace, B. Clarke, F. Borras-Cuesta, and J. Prieto. 1997. Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus. Hepatology 25:470-477.
13. Buonocore, L., K. J. Blight, C. M. Rice, and J. K. Rose. 2002. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J. Virol. 76:6865-6872.
14. Choo, Q. L., G. Kuo, R. Ralston, A. Weiner, D. Chien, G. Van Nest, J. Han, K. Berger, K. Thudium, C. Kuo, et al. 1994. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. USA 91:1294-1298.
15. Cooper, S., A. L. Erickson, E. J. Adams, J. Kansopon, A. J. Weiner, D. Y. Chien, M. Houghton, P. Parham, and C. M. Walker. 1999. Analysis of a successful immune response against hepatitis C virus. Immunity 10:439-449.
16. Cormier, E. G., R. J. Durso, F. Tsamis, L. Boussemart, C. Manix, W. C. Olson, J. P. Gardner, and T. Dragic. 2004. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc. Natl. Acad. Sci. USA 101:14067-14072.
17. Cormier, E. G., F. Tsamis, F. Kajumo, R. J. Durso, J. P. Gardner, and T. Dragic. 2004. CD81 is an entry coreceptor for hepatitis C virus. Proc. Natl. Acad. Sci. USA 101:7270-7274.
18. Deleersnyder, V., A. Pillez, C. Wychowski, K. Blight, J. Xu, Y. S. Hahn, C. M. Rice, and J. Dubuisson. 1997. Formation of native hepatitis C virus glycoprotein complexes. J. Virol. 71:697-704.
19. De Re, V., L. Caggiari, R. Talamini, M. Crovatto, S. De Vita, C. Mazzaro, R. Cannizzaro, R. Dolcetti, and M. Boiocchi. 2004. Hepatitis C virus-related hepatocellular carcinoma and B-cell lymphoma patients show a different profile of major histocompatibility complex class II alleles. Hum. Immunol. 65:1397-1404.
20. Dubuisson, J., H. H. Hsu, R. C. Cheung, H. B. Greenberg, D. G. Russell, and C. M. Rice. 1994. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J. Virol. 68:6147-6160.
21. Dubuisson, J., and C. M. Rice. 1996. Hepatitis C virus glycoprotein folding: disulfide bond formation and association with calnexin. J. Virol. 70:778-786.
22. Esumi, M., T. Rikihisa, S. Nishimura, J. Goto, K. Mizuno, Y. H. Zhou, and T. Shikata. 1999. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees. Arch. Virol. 144:973-980.
23. Ezelle, H. J., D. Markovic, and G. N. Barber. 2002. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector. J. Virol. 76:12325-12334.
24. Farci, P., A. Shimoda, D. Wong, T. Cabezon, D. De Gioannis, A. Strazzera, Y. Shimizu, M. Shapiro, H. J. Alter, and R. H. Purcell. 1996. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. USA 93:15394-15399.
25. Fernandez, M., M. Porosnicu, D. Markovic, and G. N. Barber. 2002. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol. 76:895-904.
26. Flint, M., C. Maidens, L. D. Loomis-Price, C. Shotton, J. Dubuisson, P. Monk, A. Higginbottom, S. Levy, and J. A. McKeating. 1999. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 73:6235-6244.
27. French Study Group for the Standardization of Hepatitis C Virus PCR. 1994. Improvement of hepatitis C virus RNA polymerase chain reaction through a multicentre quality control study. J. Virol. Methods 49:79-88.
28. Friedl, P., A. T. den Boer, and M. Gunzer. 2005. Tuning immune responses: diversity and adaptation of the immunological synapse. Nat. Rev. Immunol. 5:532-545.
29. Gerlach, J., H. Diepolder, M.-C. Jung, N. Gruner, W. Schruat, R. Zachoval, R. Hoffman, C. Schirren, T. Santantonio, and G. Pape. 1999. Recurrence of HCV after loss of virus specific CD4+ T cell response in acute hepatitis C. Gastroenterology 117:933-941.
30. Gremion, C., and A. Cerny. Hepatitis C virus and the immune system: a concise review. Rev. Med. Virol. 2005. 15:235-268.
31. Gruner, N. H., J. T. Gerlach, M. C. Jung, H. M. Diepolder, C. A. Schirren, W. W. Schruat, R. W. Hoffman, R. Zachoval, T. Santantonio, M. Cucchiarini, A. Cerny, and G. R. Pape. 2000. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J. Infect. Dis. 181:1528-1536.
32. Hadlock, K. G., R. E. Lanford, S. Perkins, J. Rowe, Q. Yang, S. Levy, P. Pileri, S. Abrigani, and S. K. H. Foung. 2000. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J. Virol. 74:10407-10416.
33. Hagan, D. T. O., M. Singh, C. Dong, M. Ugozolli, K. Berger, E. Glazer, M. Selby, M. Wininger, P. Ng, K. Crawford, X. Paliard, S. Coates, and M. Houghton. 2004. Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine 23:672-680.
34. Haglund, K., J. Forman, H. G. Krausslich, and J. K. Rose. 2000. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology 268:112-121.
35. Hallam, N. F., M. L. Fletcher, S. J. Read, A. M. Majid, J. B. Kurtz, and C. R. Rizza. 1993. Low risk of sexual transmission of hepatitis C virus. J. Med. Virol. 40:251-253.
36. Harris, H. E., M. E. Ramsay, N. Andrews, and K. P. Eldridge. 2002. Clinical course of hepatitis C virus during the first decade of infection: cohort study. Br. Med. J. 324:450-453.
37. Houghton, M., Q. L. Choo, D. Chien, G. Kuo, and A. Weiner. 1997. Development of an HCV vaccination for the induction of immune responses against hepatitis C virus proteins. Vaccine 15:853-856.
38. Hussy, P., H. Langen, J. Mous, and H. Jacobsen. 1996. Hepatitis C virus core protein: carboxy-terminal boundaries of two processed species suggest cleavage by a signal peptide peptidase. Virology 224:93-104.
39. Jeong, S.-H., M. Qiao, M. Nascimbeni, Z. Hu, B. Rehermann, K. Murthy, and T. J. Liang. 2004. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J. Virol. 78:6995-7003.
40. Kahn, J. S., A. Roberts, C. Weibel, L. Buonocore, and J. K. Rose. 2001. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J. Virol. 75:11079-11087.
41. Kipps, T. J., P. Parham, J. Punt, and L. A. Herzenberg. 1985. Importance of immunoglobulin isotype in human antibody-dependent, cell mediated cytotoxicity directed by murine monoclonal antibodies. J. Exp. Med. 161:1-17.
42. Lawson, N. D., E. A. Stillman, M. A. Whitt, and J. K. Rose. 1995. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. USA 92:4477-4481.
43. Lozach, P. Y., A. Amara, B. Bartosch, J. L. Virelizier, F. Arenzana-Seisdedos, F. L. Cosset, and R. Altmeyer. 2004. C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J. Biol. Chem. 279:32035-32045.
44. Lozach, P. Y., H. Lortat-Jacob, A. de Lacroix de Lavalette, I. Staropoli, S. Foung, A. Amara, C. Houles, F. Fieschi, O. Schwartz, J. L. Virelizier, F. Arenzana-Seisdedos, and R. Altmeyer. 2003. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J. Biol. Chem. 278:20358-20366.
45. Majid, A., R. Holmes, U. Desselberger, P. Simmonds, and T. A. McKee. 1995. Molecular epidemiology of hepatitis C virus infection amongst intravenous drug users in rural communities. J. Med. Virol. 46:48-51.
46. Majid, A., P. Jackson, Z. Lawal, G. M. Pearson, H. Parker, G. J. Alexander, J. P. Allain, and J. Petrik. 1999. Ontogeny of hepatitis C virus (HCV) hypervariable region 1 (HVR1) heterogeneity and HVR1 antibody responses over a 3 year period in a patient infected with HCV type 2b. J. Gen. Virol. 80:317-325.
47. Majid, A. M., and D. R. Gretch. 2002. Current and future hepatitis C virus diagnostic testing: problems and advancements. Microbes Infect. 4:1227-1236.
48. Marais, D., J. A. Passmore, J. Maclean, R. Rose, and A. L. Williamson. 1999. A recombinant human papillomavirus (HPV) type 16 L1-vaccinia virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles. J. Gen. Virol. 80:2471-2475.
49. McHutchison, J. G., and A. T. Dev. 2004. Future trends in managing hepatitis C. Gastroenterol. Clin. N. Am. 33:S51-S61.
50. Mehta, H. S., A. Cox, D. R. Hoover, H.-X. Wang, Q. Mao, S. Ray, S. A. Strathdee, D. Vlahov, and D. L. Thomas. 2002. Protection against persistence of hepatitis C. Lancet 359:1478-1483.
51. Murata, K., M. Lechmann, M. Qiao, T. Gunji, H. J. Alter, and T. J. Liang. 2003. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc. Natl. Acad. Sci. USA 100:6753-6758.
52. Obuchi, M., M. Fernandez, and G. N. Barber. 2003. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 77:8843-8856.
53. Op de Beek, A., C. Voisset, B. Bartosch, Y. Ciczora, L. Cocquerel, Z. Keck, S. Foung, F. L. Cosset, and J. Dubuisson. 2004. Characterization of functional hepatitis C virus glycoproteins. J. Virol. 78:2994-3002.
54. Pagano, J. S., M. Blaser, M. A. Buendia, B. Damania, K. Khalili, N. Raab-Traub, and B. Roizman. 2004. Infectious agents and cancer: criteria for a causal relation. Semin. Cancer Biol. 14:453-471.
55. Pancholi, P., M. Perkus, N. Tricoche, Q. Liu, and A. Prince. 2003. DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. J. Virol. 77:382-390.
56. Park, S. H., S. H. Yang, C. G. Lee, J. W. Youn, J. Chang, and Y. C. Sung. 2003. Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. Vaccine 21:4555-4564.
57. Patel, A. H., J. Wood, F. Penin, J. Dubuisson, and J. McKeating. 2000. Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J. Gen. Virol. 81:2873-2883.
58. Patel, J., A. H. Patel, and J. McLauchlan. 1999. Covalent interactions are not required to permit or stabilize the non-covalent association of hepatitis C virus glycoproteins E1 and E2. J. Gen. Virol. 80:1681-1690.
59. Pöhlmann, S., J. Zhang, F. Baribaud, Z. Chen, G. J. Leslie, G. Lin, A. Granelli-Piperno, R. W. Doms, C. M. Rice, and J. A. McKeating. 2003. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J. Virol. 77:4070-4080.
60. Polakos, N. K., D. Drane, J. Cox, P. Ng, M. Selby, D. Chien, D. T. O'Hagan, M. Houghton, and X. Paliard. 2001. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J. Immunol. 166:3589-3598.
61. Puig, M., M. E. Major, K. Mihalik, and S. M. Feinstone. 2004. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 22:991-1000.
62. Ralston, R., K. Thudium, K. Berger, C. Kuo, B. Gervase, J. Hall, M. Selby, G. Kuo, M. Houghton, and Q.-L. Choo. 1993. Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J. Virol. 67:6753-6761.
63. Rehermann, B., and M. Nascimbeni. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5:215-229.
64. Roberts, A., L. Buonocore, R. Price, J. Forman, and J. K. Rose. 1999. Attenuated vesicular stomatitis viruses as vaccine vectors. J. Virol. 73:3723-3732.
65. Roberts, A., E. Kretzschmar, A. S. Perkins, J. Forman, R. Price, L. Buonocore, Y. Kawaoka, and J. K. Rose. 1998. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J. Virol. 72:4704-4711.
66. Roberts, A., J. D. Reuter, J. H. Wilson, S. Baldwin, and J. K. Rose. 2004. Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J. Virol. 78:3196-3199.
67. Roboz, G. J. 1998. Hepatitis C and B-cell lymphoma. AIDS Patient Care STDs 12:605-609.
68. Rose, N. F., P. A. Marx, A. Luckay, D. F. Nixon, W. J. Moretto, S. M. Donahoe, D. Montefiori, A. Roberts, L. Buonocore, and J. K. Rose. 2001. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106:539-549.
69. Rosen, H. R., C. Miner, A. W. Sasaki, D. M. Lewinsohn, A. J. Conrad, A. Bakke, et al. 2002. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology 35:190-198.
70. Sarih, M., N. Bouchrit, and A. Benslimane. 2000. Different cytokine profiles of peripheral blood mononuclear cells from patients with persistent and self-limited hepatitis C virus infection. Immunol. Lett. 74:117-120.
71. Scarselli, E., H. Ansuini, R. Cerino, R. M. Roccasecca, S. Acali, G. Filocamo, C. Traboni, A. Nicosia, R. Cortese, and A. Vitelli. 2002. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21:5017-5025.
72. Snapper, C. M., and F. D. Finkelman. 1999. Immunoglobulin class switching, p. 831-861. In W. E. Paul (ed.), Fundamental immunology. Lippincott-Raven Publishers, Philadelphia, Pa.
73. Song, M. K., S. W. Lee, Y. S. Suh, K. J. Lee, and Y. C. Sung. 2000. Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice. J. Virol. 74:2920-2925.
74. Tan, S. L., Y. He, Y. Huang, and M. J. Gale, Jr. 2004. Strategies for hepatitis C therapeutic intervention: now and next. Curr. Opin. Pharmacol. 4:465-470.
75. Thimme, R., D. Oldach, K. M. Chang, C. Steiger, S. C. Ray, and F. V. Chisari. 2001. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194:1395-1406.
76. Thursz, M., R. Yallop, R. Goldin, C. Trepo, and H. C. Thomas. 1999. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. Lancet 354:2119-2124.
77. Tsai, S. L., Y. F. Liaw, M. H. Chen, C. Y. Huang, and G. C. Kuo. 1997. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25:449-458.
78. Wedemeyer, H., X. S. He, M. Nascimbeni, A. R. Davis, H. B. Greenberg, J. H. Hoofnagle, T. J. Liang, H. Alter, and B. Rehermann. 2002. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J. Immunol. 169:3447-3458.
79. Willberg, C., E. Barnes, and P. Klenerman. 2003. HCV immunology-death and the maiden T cell. Cell Death Differ. 10(Suppl. 1):S39-S47.
80. Yasui, K., T. Wakita, K. Tsukiyama-Kohara, S.-I. Funahashi, M. Ichikawa, T. Kajita, D. Moradpour, J. R. Wands, and M. Kohara. 1998. The native form and maturation process of hepatitis C virus core protein. J. Virol. 72:6048-6055.